Trial Profile
Combination immunotherapy for lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs CD40L GVAX (Primary) ; Cyclophosphamide; Tretinoin
- Indications Lung cancer
- Focus Therapeutic Use
- 10 Dec 2012 Planned end date changed from 1 Jan 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 09 Jul 2012 Planned end date changed from 1 Aug 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 21 Feb 2012 Planned end date changed from 1 Mar 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.